UMQVC members will be at the 23rd annual conference of ISOQOL for oral communications and a poster:
- Friday, 21 october
Poster #2009 : Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: results of the GERCOR DREAM phase III trial. Amélie Anota, Dewi Vernerey, Christophe Tournigand, Benoist Chibaudel, Benoit Samson, Werner Scheithauer, David Brusquant, Thierry André, Aimery de Gramont, Franck Bonnetain
Oral Session 210: Statistical Methods
4:20 pm – 4:33 pm Impact on time until deterioration of health-related quality of life of a first-line therapy combining ABI-007 and gemcitabine or simplified LV5FU2 in patients with metastatic pancreatic cancer: results of clinical phase II trial AFUGEM. Emilie Charton, Jean-Baptiste Bachet, Benoist Chibaudel, Pierre Validire, Pascal Hammel, Thierry André, Christophe Louvet, Amélie Anota, Franck Bonnetain
4:34 pm – 4:47 pm Impact of the occurrence of missing data on the time to health-related quality of life score deterioration: a simulation study. Amélie Anota, Francesco Cottone, Fabio Efficace, Franck Bonnetain
- Saturday, 22 october
Oral Session 301: Response Shift
4:51 pm – 5:04 pm Impact of the occurrence of a response shift on the determination of the minimal clinically important difference in a health-related quality of life score over time. Ahmad Ousmen, Thierry Conroy, Francis Guillemin, Michel Velten, Damien Jolly, Mariette Mercier, Sylvain Causeret, Jean Cuisinier, Olivier Graesslin, Zeinab Hamidou, Franck Bonnetain, Amélie Anota
Link to ISOQOL conference website
